In addition to SARS-CoV-2 and its variants, emerging viruses that cause respiratory viral infections will continue to arise. Increasing evidence suggests a delayed, possibly suppressed, type 1 interferon (IFN-I) response occurs early during COVID-19 and other viral respiratory infections such as SARS and MERS. These observations prompt considering IFN-β as a prophylactic or early intervention for respiratory viral infections. A rationale for developing and testing intranasal interferon beta (IFN-β) as an immediately available intervention for new respiratory viral infections that will arise unexpectedly in the future is presented and supported by basic and clinical trial observations. IFN-β prophylaxis could limit the spread and consequences of an emerging respiratory viral infection in at-risk individuals while specific vaccines are being developed.
【저자키워드】 COVID-19, coronavirus, Prophylaxis, nasopharyngeal, post-pandemic, emerging respiratory viral infection, type-I interferon, 【초록키워드】 SARS-CoV-2, Vaccine, clinical trial, Intervention, Prophylactic, MERS, virus, variants, Spread, IFN-I, respiratory viral infection, intranasal, respiratory viral infections, Evidence, interferon beta, observation, IFN-β, individual, viral respiratory infection, type 1 interferon, limit, consequence, addition, supported, occur, suppressed, Increasing, 【제목키워드】 respiratory, Against,